Amgen Inc. v. Sandoz Inc.

United States Supreme Court – 2017

“Biologics and biosimilars — patent dance is optional, not mandatory.”

SHORT DESCRIPTION

Amgen Inc. v. Sandoz Inc. is a landmark U.S. Supreme Court decision interpreting the Biologics Price Competition and Innovation Act (BPCIA). The case clarified procedural requirements governing biosimilar drug approvals, particularly whether certain information exchanges — commonly called the “patent dance” — are mandatory.

The ruling significantly shaped the legal framework for biologics and biosimilar competition in the United States.

FACTS OF THE CASE

Amgen manufactured Neupogen, a biologic drug used to treat patients with low white blood cell counts. Sandoz sought FDA approval to market a biosimilar version under the abbreviated pathway established by the BPCIA.

Under the statute, a biosimilar applicant may provide its application and manufacturing information to the reference product sponsor, initiating a structured exchange process known as the “patent dance.”

Sandoz chose not to provide its application information to Amgen and instead provided notice of commercial marketing before receiving FDA approval.

Amgen filed suit, arguing that compliance with the patent dance and post-approval notice were mandatory statutory requirements.

ISSUES INVOLVED

Is participation in the “patent dance” mandatory under the BPCIA?

Must notice of commercial marketing be given only after FDA approval?

COURT’S FINDINGS AND OBSERVATIONS

The Supreme Court held that the patent dance is not mandatory. A biosimilar applicant may choose not to provide its application information, though it may face certain litigation consequences.

The Court also ruled that notice of commercial marketing may be given before FDA approval, rejecting Amgen’s argument that notice must follow approval.

The decision emphasized statutory interpretation and congressional intent, confirming that the BPCIA provides flexibility rather than rigid procedural obligations.

SUGGESTION / PRACTICAL TAKEAWAY

This judgment has major implications for biologics and biosimilar manufacturers. Strategic decisions regarding participation in the patent dance can significantly affect litigation timing and competitive positioning.

Both reference product sponsors and biosimilar applicants must carefully evaluate litigation risk, timing, and disclosure strategies under the BPCIA framework.

JUDGMENT

Year: 2017

The United States Supreme Court held that the patent dance is optional and that notice of commercial marketing need not await FDA approval.